Evidence map›Paper›PMID 36509928›Full record

ArticleEndocrine2023

Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.

F Sesti, G Puliani, T Feola, F Campolo, F Sciarra, V Hasenmajer, A Lenzi, A Faggiano, A M Isidori, M A Venneri and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

F SestiDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
G PulianiDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
T FeolaDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
F CampoloDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
F SciarraDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
V HasenmajerDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
A LenziDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
A FaggianoDepartment of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
A M IsidoriDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy.
M A VenneriDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy. maryanna.venneri@uniroma1.it.
E GiannettaDepartment of Experimental Medicine Sapienza University of Rome, Rome, Italy. elisa.giannetta@uniroma1.it.ORCID 0000-0003-3614-6151
Sapienza University of Rome · ITAzienda Ospedaliera Sant'Andrea · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe immune environment represents a new, but little explored, tool for understanding neuroendocrine neoplasms (NENs) behavior. An immunosuppressed microenvironment is hypothesized to promote NENs progression. A missing profiling of circulating leukocyte and peripheral blood mononuclear cells (PBMCs) subpopulations would open new perspectives in the still limited diagnostic-therapeutic management of NENs.

methodsA cross-sectional case-control pilot study was performed recruiting 30 consecutive subjects: 15 patients naïve to treatment, with histologically proven gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and 15 healthy controls, matched for age and sex. PBMCs subpopulations were studied by flow cytometry. Soluble Tie2 (sTie2), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2) were evaluated by ELISA.

resultsImmune cell profiling revealed a significant lower CD3

conclusionsPatients with GEP-NET presented an immunosuppressed environment characterized by a low count of cytotoxic NK cells, a high count of anti-inflammatory non-classical monocytes, and a low count of T-helper lymphocytes. Higher levels of TEMs and angiopoietins suggest a crosstalk between innate immunity and angiogenic pathways in NETs.

Indexed as

AngiopoietinsNeuroendocrine TumorsReceptor, TIE-2Cross-Sectional StudiesHumansIntestinal NeoplasmsLeukocytes, MononuclearPancreatic NeoplasmsPilot ProjectsStomach NeoplasmsTumor MicroenvironmentAngiopoietinsReceptor, TIE-2AngiogenesisAngiopoietinImmune profileNeuroendocrine neoplasmsPBMCsTie2

Identifiers

PMID36509928
OpenAlexW4311280182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.